Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer. Ma S, Zhang L, Ren Y, Dai W, et al. Oncogene 2021 Mar 9. pii: 10.1038/s41388-021-01734.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ma S, Zhang L, Ren Y, Dai W, et al. Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer. Oncogene 2021 Mar 9. pii: 10.1038/s41388-021-01734.
PMID: 33750895